Haemonetics CFO has 655 shares withheld for tax

Haemonetics EVP and CFO James DArecca reported a small tax-related share disposition.

Rhea-AI Filing Summary

Haemonetics EVP and CFO James DArecca reported a small tax-related share disposition. On May 1, 2026, 655 shares of Haemonetics common stock were withheld at $59.26 per share to cover tax obligations from vesting restricted stock units. This was not an open-market sale. After the withholding, DArecca directly owned 27,637 shares, which includes previously reported unvested RSUs.

Insider Trade Summary

Exercise Price or Tax Liability: 655 shares

Exercise Price or Tax Liability 1 txn

Insider DArecca James

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	655	$59.26	$39K

Holdings After Transaction: Common Stock — 27,637 shares (Direct)

Footnotes (2)

1. F1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
2. F2. This number includes unvested RSUs previously reported.

Key Figures

Tax-withheld shares: 655 shares Withholding price: $59.26 per share Shares held after transaction: 27,637 shares

3 metrics

Tax-withheld shares 655 shares Shares withheld for tax obligations on RSU vesting on May 1, 2026

Withholding price $59.26 per share Value used for the 655 tax-withheld shares

Shares held after transaction 27,637 shares Direct holdings after tax-withholding disposition, including unvested RSUs

Key Terms

restricted stock units ("RSUs"), withheld for tax obligations, tax-withholding disposition, Common Stock

4 terms

restricted stock units ("RSUs") financial

"vesting of certain restricted stock units ("RSUs") previously reported in Table I"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

withheld for tax obligations financial

"Represents shares withheld for tax obligations in connection with the vesting"

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Haemonetics (HAE) report for CFO James DArecca?

Haemonetics reported that CFO James DArecca had 655 shares withheld to cover tax obligations from vesting restricted stock units. This Form 4 event reflects a tax-withholding disposition, not an open-market purchase or sale of Haemonetics common stock.

Was the Haemonetics (HAE) CFO’s Form 4 transaction an open-market stock sale?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. 655 shares were withheld by the company at $59.26 per share to satisfy tax obligations arising from previously granted restricted stock units that vested on May 1, 2026.

How many Haemonetics (HAE) shares does CFO James DArecca hold after this Form 4?

Following the reported tax withholding, CFO James DArecca directly holds 27,637 shares of Haemonetics common stock. This figure includes unvested restricted stock units previously reported, providing the updated total equity position visible in this particular insider filing.

What was the price used for the Haemonetics (HAE) CFO tax-withholding shares?

The 655 shares withheld for the CFO’s tax obligations were valued at $59.26 per share. This price is used solely for calculating the tax-withholding disposition related to the vesting of restricted stock units and does not represent an open-market trade price.

What triggered the Haemonetics (HAE) CFO’s tax-withholding transaction on the Form 4?

The transaction was triggered by the vesting of previously granted restricted stock units. To satisfy associated tax obligations, 655 shares of Haemonetics common stock were withheld, as explained in the Form 4 footnote describing the RSU vesting and resulting share disposition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DArecca James

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		F		655(1)	D	$59.26	27,637(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

2. This number includes unvested RSUs previously reported.

	/s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)